[ TRANSACTION RECORD ]

Bristol Myers Squibb Investment in Karuna Therapeutics — 2023

VERIFIED VECTOR ID: 001560 · tx-088
M SOURCE NODE — FUNDER
Bristol Myers Squibb
Healthcare United States
$14,000,000,000
EQUITY
22/12/2023
Q DESTINATION NODE — RECIPIENT
Karuna Therapeutics
Company United States
Amount (USD)
$14.0B
Flow Type
EQUITY
Transaction Date
22/12/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity Bristol Myers Squibb
AUM 110000
HQ Location United States
Sector Healthcare
Recipient Profile [ Q ]
Entity Karuna Therapeutics
Entity Type Company
Jurisdiction United States
Intelligence Note

Bristol Myers Squibb entered into an agreement to acquire Karuna Therapeutics for 14 billion dollars to expand its presence in neuroscience and psychiatric medicine. The transaction centers on Karuna’s novel treatment for schizophrenia, KarXT. This deal highlights the high institutional value of transformative neurological therapies in the global healthcare market.

Σ
Primary Forensic Source https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-to-Acquire-Karuna-Therapeutics/
✓ SOURCE LINKED